A recent study by Giovatto et al. (2024) suggests that more education is needed on biosimilar options. The authors surveyed US prescribers and health system specialty pharmacists in rheumatology, dermatology, and gastroenterology. Results showed that only a small percentage of prescribers and pharmacists felt “very prepared” to discuss biosimilar options with patients. Additionally, a significant portion of prescribers and pharmacists were unsure about regulations regarding interchangeability and substitution of biosimilars. See the key findings below:
Only 16.0% of prescribers and 13.4% of pharmacists reported feeling “very prepared” to have conversations with patients about biosimilar options.
Read the full paper here.
. If the provided articles seems to be less than 200 characters or it is an intro of the author, then try to generate an articles using this title.Are providers ready for biosimilars? – Healthcare Economist
